RNAZ TransCode Therapeutics, Inc.
$1.67▼ -2.08%
Healthcare
Other
Volume 7.5K
Avg Volume (10D) 34.3K
Key Metrics & Fundamentals
Market Cap
$28.27M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.52 - 13.21
% vs 50 MA
-13.07%
% vs 200 MA
-73.28%
RSI-14
41.9
MACD Histogram
+0.0400
Beta (1Y vs SPY)
0.83
Free Cash Flow
-$5.40M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.69M
COGS
–
Operating Exp
$6.21M
Operating Income
-$6.21M
EBIT
-$6.21M
Pretax Income
-$6.75M
Net Income
-$6.75M
EPS (Diluted)
-7.17
Price & Volume History
Loading chart…
Recent News
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
PR Newswire · Oct 26, 2026 7:31 AM ET
Natera Partners With TransCode to Advance Colorectal Cancer Trial
Zacks · Oct 21, 2026 9:16 AM ET
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
PR Newswire · Oct 19, 2026 8:04 AM ET
Natera, TransCode Collaborate to Improve Enrollment for Colorectal Cancer Trial
MT Newswires · Oct 13, 2026 7:53 AM ET
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Business Wire · Oct 13, 2026 7:30 AM ET
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
PR Newswire · Sep 28, 2026 8:04 AM ET
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
PR Newswire · Sep 22, 2026 8:04 AM ET
Join Today's Live Investor Webinar with TransCode Therapeutics
ACCESS Newswire · Sep 16, 2026 9:00 AM ET
TransCode Therapeutics Announces Leadership Transition
PR Newswire · Sep 10, 2026 4:10 PM ET
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
ACCESS Newswire · Sep 3, 2026 9:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See RNAZ's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.